Cristina Festari

List of Publications by Year
in descending order

23 papers	1,799 citations	516710 16 h-index	713466 21 g-index
23 all docs	23 docs citations	23 times ranked	2674 citing authors

#	ARTICLE	IF	CITATIONS
1	Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiology of Aging, 2017, 49, 60-68.	3.1	870
2	Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 683-697.	2.6	183
3	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology, 2018, 25, 1201-1217.	3.3	153
4	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	6.4	86
5	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurology, 2016, 73, 1417.	9.0	84
6	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	6.4	81
7	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	6.4	61
8	Comparison of Bioinformatics Pipelines and Operating Systems for the Analyses of 16S rRNA Gene Amplicon Sequences in Human Fecal Samples. Frontiers in Microbiology, 2020, 11, 1262.	3.5	36
9	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	6.4	35
10	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496.	6.4	35
11	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1526-1533.	6.4	28
12	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1546-1556.	6.4	24
13	The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 247-255.	6.4	23
14	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	6.4	22
15	Italian consensus recommendations for a biomarker‐based aetiological diagnosis in mild cognitive impairment patients. European Journal of Neurology, 2020, 27, 475-483.	3.3	20
16	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	6.4	19
17	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid‐PET. Alzheimer's and Dementia, 2018, 14, 1088-1098.	0.8	15
18	Medial temporal lobe atrophy and posterior atrophy scales normative values. NeuroImage: Clinical, 2019, 24, 101936.	2.7	12

#	Article	IF	Citations
19	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. Neurodegenerative Diseases, 2016, 16, 111-117.	1.4	6
20	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 414-421.	0.7	5
21	ICâ€Pâ€071: THE EFFECT OF APOE ON WHITE MATTER LESIONS. Alzheimer's and Dementia, 2018, 14, P63.	0.8	1
22	The incremental diagnostic value of 18F-Florbetapir imaging in naturalistic patients with cognitive impairment: final results from the india-FBP study. Neurobiology of Aging, 2016, 39, S27.	3.1	0
23	P4â€064: THE EFFECT OF APOE ON WHITE MATTER LESIONS. Alzheimer's and Dementia, 2018, 14, P1457.	0.8	0